3.21
3.21 (0%)
As of Dec 27, 2024
Arbutus Biopharma Corp [ABUS]
Source:
Company Overview
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
| Country | United States |
| Headquarters | warminster, pennsylvania |
| Phone Number | 604-419-3200 |
| Industry | manufacturing |
| CEO | Michael J. Mcelhaugh |
| Website | www.arbutusbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $6.2 |
| Operating Profit | $-76.3 |
| Net Income | $-69.9 |
| Net Cash | $10 |
Profit Ratios
| Gross Margin | $6.2 |
| Operating Margin | -1,236.7 |
| Profit as % of Revenues | -8.8% |
| Profit as % of Assets | -50.7% |
| Profit as % of Stockholder Equity | -71.8% |
Management Effectiveness
| Return on Equity | -71.8% |
| Return on Assets | -53.1% |
| Turnover Ratio | 4.5% |
| EBITA | $-76.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $131.7 |
| Total Liabilities | $34.3 |
| Operating Cash Flow | $-64.9 |
| Investing Cash Flow | $22.9 |
| Financing Cash Flow | $52 |
